UBS Upgrades Array BioPharma (ARRY) to Buy
More News related to ARRY
- Array BioPharma to Present at the Piper Jaffray Healthcare Conference
- UBS Upgrades Array BioPharma (ARRY) to Buy
- Array BioPharma (ARRY) Reports Q1 Loss of $0.52, Beats by 3c
- Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010
- Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2010 on November 2, 2009
More News related to Upgrades
- Waterside Capital (WSCC) Reports a Quarterly Loss
- Ship Finance (SFL) Posts Q3 adj.-EPS of $0.47, Misses Estimates
- Frontline (FRO) Posts Q3 Loss of $0.07, Beats Street by 5c
UBS upgrades Array BioPharma (Nasdaq: ARRY) from Neutral to Buy. Price target $3.25.
To see more analyst ratings on ARRY Click Here.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer, inflammatory, and metabolic diseases in North America, Europe, and Asia Pacific.
Related Categories
UpgradesStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
